Q-omics provides the consensus-scored GRK6P1 profile across patient tissues and cancer cell-line models. GRK6P1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GRK6P1 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, GRK6P1 RNA expression shows 14,193 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight ACC, COAD, and PCPG as cancer lineages where GRK6P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRK6P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRK6P1 survival associations across molecular data types. GRK6P1 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRK6P1 RNA expression–survival associations across cancer types. High GRK6P1 expression shows unfavorable associations in ACC, LIHC and KICH, but favorable associations in SKCM, THYM and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GRK6P1 RNA expression.
This table summarizes GRK6P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for GRK6P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRK6P1 shows higher tumor expression in COAD, KIRP, LIHC, STAD, KIRC and CHOL. The COAD box plot shows higher GRK6P1 RNA expression in tumor versus normal tissue (log2 FC = +0.409, t-test p < 0.001).
This table shows molecular features associated with GRK6P1 in patient tissues and cancer cell lines. In patient samples, GRK6P1 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, GRK6P1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST.
